Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 [motesanib] Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer.

Next Previous
Trial Profile

An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 [motesanib] Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motesanib (Primary) ; Cisplatin; Gemcitabine; Panitumumab
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Amgen

Most Recent Events

  • 19 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and efficacy to safety only as reported by ClinicalTrials.gov record.
  • 24 Mar 2009 Primary outcome amended as reported by ClinicalTrials.gov.
  • 24 Mar 2009 Planned end date (Feb 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top